Preview

ЕВРОПЕЙСКИЙ КОНСЕНСУС ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ ИЗ ФОЛЛИКУЛЯРНОГО ЭПИТЕЛИЯ

https://doi.org/10.14341/ket20062310-30

Полный текст:

Об авторе

- -



Список литературы

1. Coleman P.M., Babb P., Damiecky P. et al. Cancer Survival Trends in England and Wales 1971-1995: Deprivation and NHSRegion Series SMPS no. 61. P. 471-478. London: Stationery Office, 1999.

2. Hodgson N.C., Button J., Solorzano C.C. Thyroid cancer: is the incidence still increasing? // Ann. Surg. Oncol. 2004. V. 11. P. 1093-1097.

3. Guidelines for the Management of Thyroid Cancer in Adults. Ed. Publication Unit of the Royal College of Physicians. London: British Thyroid Association and Royal College of Physicians, 2002.

4. Rodrigues FJ.C., Limbert E.S., Marques A.P. et al. Thyroid Study Group. Protocol for the treatment and follow-up of differentiated follicular thyroid carcinomas. Portuguese Medical Minutes, 2005.

5. Trattamento e Follow-up del Carcinoma Tiroideo Dijferenziato della Tiroide. Linee Guida SIE-AIMN-AIFM, 2004.

6. Van De Velde C.J.H., Hamming J.F., Goslings B.M. et al. Report of the consensus development conference on the management of differentiated thyroid cancer in The Netherlands // Eur. J. of Canc/ and Clinical. Oncol. 1988. V. 24. P. 287-292.

7. Pacini F., Burroni L., Ciuoli C. et al. Management of thyroid nodules: a clinicopathological, evidence-based approach // Eur. J. of Nucl. Med. and Molec. Imaging. 2004. V. 31. P. 1443-1449.

8. Belfiore A., La Rosa G.L., La Porta G.A. et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine uptake, sex, age, and multinodularity // Am. J. of Med. 1992. V. 93. P. 363-369.

9. Marqusee E., Benson C.B., Prates M.C. et al. Usefulness of ultrasonography in the management of nodular thyroid disease // Ann. of Int. Med. 2000. V. 133. P. 696-700.

10. Frates M.C., Benson C.B., Charboneau J.W. et al. Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement // Radiol. 2005. V. 237. P. 794-800.

11. Hegedus L. Thyroid ultrasound // Endocrinol. and Met. Clin. of N. Am. 2001. V. 30. P. 339-360.

12. Cap J., Riska A., Rehorkova P. et al. Sensitivity and specificity of the fine needle aspiration biopsy of the thyroid: clinical point of view // Clin/ Endocr. 1999. V. 51. P. 509-515.

13. Braga M., Cavalcanti T.C., Collaco L.M., Graf H. Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules // J. of Clin. Endocr. and Met. 2001. V. 86. P. 4089-4091.

14. Mulcahy M.M., Cohen J.I., Anderson P.E. Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of well-differentiated thyroid cancer // Laryngoscope. 1998. V. 104. P. 494-496.

15. Giuffrida D., Gharib H. Anaplastic thyroid cancer: current diagnosis and treatment // Ann. of Oncol. 2000. V. 11. P. 1083-1089.

16. Mazzaferri E.L., Jhiang S.M. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer // Am. J. of Med. 1994. V. 49. P. 418-428.

17. Goldstein R.E., Netterville J.L., Burkey B., Johnson J.E. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules // Ann. of Surg. 2002. V. 235. P. 656-662; discussion. P. 662-664.

18. Guarino E., Tarantini B., Pilli T. et al. Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer //Thyroid. 2005. V. 15. P. 1041-1045.

19. Elisei R., Bottici V., Luchetti F. et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders // J. of Clin.Endocr. and Met. 2004. V. 89. P. 163-168.

20. Niccoli P., Wion-Barbot N., Caron P. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group // J. of Clin. Endocr. and Met. 1997. V. 82. P. 338-341.

21. Rieu M., Lame M.C., Richard A. et al. CT prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules // Clin. Endocr. (Oxford). 1995. V. 42. P. 453-460.

22. Vierhapper H., Raber W., Bieglmayer C. et al. Routine measurement of plasma calcitonin in nodular thyroid diseases // J. of Clin. Endocr. and Met. 1997. V. 82. P. 1589-1593.

23. Shimamoto K., Satake H., Sawaki A. et al. Preoperative staging of thyroid papillary carcinoma with ultrasonography // Eur. J. of Radio.1998. V. 29. P. 4-10.

24. Esnaola N.F., Cantor S.B., Sherman S.I. et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis // Surg. 2001. V. 130. P. 921-930.

25. Hay I.D., Bergstralh E.J., Goellner J.R. et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 // Surg. 1993. V. 114. P. 1050-1058.

26. Hay I.D., Grant C.S., Bergstralh E.J. et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? // Surg. 1998. V. 124. P. 958-966.

27. Hundahl S.A., Cady B., Cunningham M.P. et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996 // Cancer. 2000. V. 89. P. 202-217.

28. Machens A., Holzhausen H.J, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma // Cancer. 2005. V. 103. P. 2269-2273.

29. Gardner R.E., Tuttle R.M., Burman K.D. et al. Prognostic importance of vascular invasion in papillary thyroid carcinoma // Arch. of Otolaryngol. - Head and Neck Surg. 2000. V. 126. P. 309-312.

30. Pacini F., Elisei R., Capezzone M. et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients // Thyroid. 2001. V. 11. P. 877-881.

31. Machens A., Hinze R., Lautenschlager C. Prophylactic completion thyroidectomy for differentiated thyroid carcinoma: prediction of extrathyroidal soft tissue infiltrates // Thyroid. 2001. V. 11. P. 381-384.

32. Randolph G.W., Daniels G.H. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid // Thyroid. 2002. V. 12. P. 989-996.

33. Ito Y., Tomoda C., Uruno T. et al. Preoperative ultrasono-graphic examination for lymph node metastases: usefulness when designing lymph node dissection for papillary microcarci-noma of the thyroid // World J. of Surg. 2004. V. 28. P. 498-501.

34. Machens A., Hinze R., Thomusch O., Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer // World J. of Surg. 2002. V. 26. P. 22-28.

35. Scheumann G.F., Gimm O., Wegener G. et al. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer // World J. of Surg. 1994. V. 18. P. 559-568.

36. Tisell L.E., Nilsson B., Molne J. et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection //World J. of Surg. 1996. V. 20. P. 854-859.

37. Dralle H., Brauckhoff M., Machens A., Gimm O. Surgical management of advanced thyroid cancer invading the aerodiges-tive tract. In Textbook of Endocrine Surgery, 2nd edn, pp 318-333. Eds OH Clark, QY Duh & E Kebebew. Philadelphia: Elsevier Saunders, 2005.

38. Thomusch O., Sekulla C., Walls G. Analysis of surgery-related complications in thyroid carcinoma -a German prospective multicentre study with 275 patients // Ada Chirurg. Austr. 2001. V. 33. P. 194-198.

39. Hartl D.M., Travagli J.P., Leboulleux S. et al.Current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery // J. of Clin. Endocr. and Met.m 2005. V. 90. P. 3084-3088.

40. Samaan N.A., Schultz P.N., Hickey R.C. et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients // J. of Clin. Endocr. and Met. 1992. V. 75. P. 714-720.

41. Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer: long-term impact of initial therapy // Trans. of the Am. Clin. and Climatol. Assoc. 1994. V. 106. P. 151-168; discussion. P. 168-170.

42. Taylor T., Specker B., Robbins J. et al. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma // Ann. of Int. Med. 1998. V. 129.P. 622-627.

43. Sawka A.M., Thephamongkhol K., Brouwers M. et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer // J. of Clin. Endocr. and Met. 2004. V. 89. P. 3668-3676.

44. Pacini F., Schlumberger M., Harmer C. et al. Post surgical use of radioiodine (1-131) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation. A consensus report // Eur. J. of Endocr. 2005. V. 153. P. 651-659.

45. Schroder P.R., Haughen B.R., Pacini F. et al. A comparison of short term changes in health related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with rhTSH compared to thyroid hormone withdrawal // J. of Clin. Endocr. and Met. 2006. V. 91. P. 878-884.

46. Schlumberger M., Charbord P., Fragu P. et al. Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels // J. of Clin. Endocr. and Met. 1980. V. 51. P. 513-519.

47. Robbins R.J., Larson S.M., Sinha N. et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation // J. of Nucl. Med. 2002. V. 43. P. 1482-1488.

48. Pacini F., Ladenson P.W., Schlumberger M. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study // J. of Clin. Endocr. and Met. 2006. V. 91. P. 926-932.

49. Park H.M., Park Y.H., Zhou X.H. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma // Thyroid. 1997. V. 7. P. 277-280.

50. Hilditch T.E., Dempsey M.R., Bolster A.A. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic -131 and 1-123 // Eur. J.of Nucl. Med. and Mol. Imaging. 2002. V. 29. P. 783-788.

51. Lassmann M., Luster M., Hanscheid H., Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants // J. of Nucl. Med. 2004. V. 45. P. 619-625.

52. Pluijmen M.J., Eustatia-Rutten C., Goslings B.M. et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma // Clini. Endocr. (Oxford). 2003. V. 58. P. 428-435.

53. Fatourechi V., Hay I.D., Mullan B.E. et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? // Thyroid. 2000. V. 10. P. 573-577.

54. Sherman S.I., Tielens E.T., Sostre S. et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma // J. of Clin. Endocr. and Met. 1994. V. 78. P. 629-634.

55. Hay I.D., Bergstralh E.J., Goellner J.R. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 // Surg. 1993. V. 114. P. 1050-1057; discussion. P. 1057-1058.

56. Hay I.D., Thompson G.B., Grant C.S. et al. Papillary thyroid carcinoma managed at the May Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients // World J. of Surg. 2002. V. 8. P. 879-885.

57. Byar D.P., Green S.B., Dor P. et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group // Eur. J. of Canc. 1979. V. 15. P. 1033-1041.

58. Tenvall J., Biorklund A., Moller T. et al. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up // Canc. 1986. V. 57. P. 1405-1414.

59. Shaha A.R., Loree T.R., Shah J.P. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid // Surg. 1995.V. 118. P. 1131-1136; discussion. P. 1136-1138.

60. Sherman S.I., Brierley J.D., Sperling M. et al.Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group // Canc. 1998. V. 83. P. 1012-1021.

61. Links T.P., van Tol K.M., Jager P.L. et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis // Endocr.-rel. Canc. 2005. V. 12. P. 272-280.

62. Wittekind C., Compton C.C., Greene F.L., Sobin L.H. TNM residual tumor classification revisited // Canc. 2002. V. 94. P. 2511-2516.

63. Cooper D.S., Specker B., Ho M. et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry // Thyroid. 1998. V. 8. P. 737-744.

64. McGriff N.J., Csako G., Gourgiotis L. et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer // Ann. of Med. 2002. V. 34. P. 554-564.

65. Baudin E., Do Cao C., Cailleux A.F. et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients // J. of Clin.Endocr. and Met. 2003. V. 88. P. 1107-1111.

66. Schlumberger M., Berg G., Cohen O. et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective // Eur. J. of Endocr. 2004. V. 150. P. 105-112.

67. Biondi B., Filetti S., Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment // Nat. Clin.l Pract. Endocr. and Met. 2005. V. 1. P. 32-40.

68. Home M.K., Singh K.K., Rosenfeld K.G. Is thyroid hormone suppression therapy prothrombotic? // J. of Clin. Endocr. and Met. 2004. V. 89. P. 4469-4473.

69. Feldt-Rasmussen U., Profilis C., Colinet E. et al. Human thyroglobulin reference material (CRM 457). 1st part: assessment of homogeneity, stability and immunoreactivity // Ann. de Biol. Clin. Paris. 1996. V. 54. P. 337-342.

70. Feldt-Rasmussen U., Profilis C., Colinet E. et al. Human thyroglobulin reference material (CRM 457). 2nd part: physicochemical characterization and certification // Ann. de Biol. Clin. Paris. 1996. V. 54. P. 343-348.

71. Chiovato L., Latrofa F., Braverman L.E. et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens // Ann. of Int. Med. 2003. V. 139. P. 346-351.

72. Cailleux A.F., Baudin E., Travagli J.P. et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? // J. of Clin. Endocr. and Met. 2000. V. 85. P. 175-178.

73. Pacini F., Capezzone M., Elisei R., Ceccarelli C. et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment // J. of Clin. Endocr. and Met. 2002. V. 87. P. 1499-1501.

74. Pacini F., Molinaro E., Castagna M.G. et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma // J. of Clin. Endocr. and Met. 2003. V. 88. P. 3668-3673.

75. Torlontano M., Attard M., Crocetti U. et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metas-tases // J. of Clin. Endocr. and Met. 2004. V. 89. P. 3402-3407.

76. Pacini F., Molinaro E., Lippi F. et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma // J. of Clin. Endocr. and Met. 2001. V. 86. P. 5686-5690.

77. Schlumberger M., Arcangioli O., Piekarski J.D. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays // J. of Nucl. Med. 1988. V. 29. P. 1790-1794.

78. Pineda J.D., Lee T., Ain K. et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan // J. of Clin. Endocr. and Met. 1995. V. 80. P. 1488-1492.

79. Pacini F., Agate L., Elisei R. et al. Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients // J. of Clin. Endocr. and Met. 2001. V. 86. P. 4092-4097.

80. Luster M., Lippi F., Jarzab B. et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review // Endocr.-rel. Canc. 2005. V. 12. P. 49-64.

81. Haugen B.R., Pacini F., Reiners C. et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer // J. of Clin. Endocr. and Met. 1999. V. 84. P. 3877-3885.

82. Driedger A.A., Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin // J. of Clinical Endocr. and Met. 2004. V. 89. P. 585-590.

83. Wang W., Macapinlac H., Larson S.M. et al. [18F]-2-fluoro-2-deoxy-o-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels // J. of Clin. Endocr. and Met. 1999. V. 84. P. 2291-2302.

84. Helal B.O., Merlet P., Toubert M.E. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy // J. of Nucl. Med. 2001. V. 42. P. 1464-1469.

85. Chin B.B., Patel P., Cohade C. et al. Recombinant human thyrotropin stimulation of fluoro-o-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma // J. of Clin. Endocr. and Met. 2004. V. 89. P. 91-95.

86. Nahas Z., Goldenberg D., Fakhry C. et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma // Laryngoscope. 2005. V. 115. P. 237-243.

87. Robbins R.J., Wan Q., Grewal R.K. et al. Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning //J. of Clin. Endocr. and Met.. 2006. V. 91. P. 498-505.

88. Schlumberger M., Pacini F., Wiersinga W.M. et al. Follow-up and management of differentiated thyroid carcinoma: European perspective in clinical practice // Eur. J. of Endocr. 2004. V. 151. P. 539-548.

89. Schlumberger M., Ricard M., Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients // Eur. J. of Endocr.. 2000. V. 143. P. 557-563.

90. Mazzaferri E.L., Robbins R.J., Spencer C.A. et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma // J. of Clin. Endocr. and Met. 2003. V. 88. P. 1433-1441.

91. Leeper R.D.The effect of 1311 therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma // J. of Clin. Endocr. and Met. 1973. V. 36. P. 1143-1152.

92. Beierwaltes W.H., Nishiyama R.H., Thompson N.W. et al. Survival time and ‘cure’ in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy // J. of Nucl. Med. 1982. V. 23. P. 561-568.

93. Bernier M.O., Leenhardt L., Hoang C. et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas // J. of Clin. Endocr. and Met. 2001. V. 86. P. 1568-1573.

94. Pacini F., Cetani F., Miccoli P. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine // World J. of Surg. 1994. V. 18. P. 600-604.

95. Pons F., Carrio I., Estorch M. et al. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma // Clin. Nucl. Med. 1987. V. 12. P. 644-647.

96. Koong S.S., Reynolds J.C., Movius E.G. et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma J. of Clin. Endocr. and Met. 1999. V. 84. P. 912-916.

97. Zettinig G., Fueger B.J., Passler C. et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy? // Clin. Endocr. (Oxford). 2002. V. 56. P. 377-382.

98. Pittas A.G., Adler M., Fazzari M. et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients // Thyroid. 2000. V. 10. P. 261-268.

99. Schlumberger M., Challeton C., De Vathaire F. et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma // J. of Nucl. Med. 1996. V. 37. P. 598-605.

100. Marcocci C., Pacini F., Elisei R. et al. Clinical and biological behaviour of bone metastases from differentiated thyroid carcinoma // Surg. 1989. V. 106. P. 960.

101. Me Williams R.R., Giannini C., Hay I.D. et al. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years // Cancer. 2003. V. 98. P. 356-362.

102. Mandel S.J., Mandel L. Radioactive iodine and the salivary glands // Thyroid. 2003. V. 13. P. 265-271.

103. Nakada K., Ishibashi T., Takei T. et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? // J. of Nucl. Med. 2005. V. 46. P. 261-266.

104. Ceccarelli C., Battisti P., Gasperi M. et al. Radiation dose to the testes after 131-1 therapy for ablation of post-surgical thyroid remnants in patients with differentiated thyroid cancer // J. of Nucl. Med. 1999. V. 40. P. 1716-1721.

105. Pacini F., Gasperi M., Fugazzola L. et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine // J. of Nucl. Med. 1994. V. 35. P. 1418-1422.

106. Schlumberger M., De Vathaire F., Ceccarelli C. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients // J. of Nucl. Med. 1996. V. 37. P. 606-612.

107. Ceccarelli C., Benicivelli W., Morciano D. Ml therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study // J. of Clin. Endocr. and Met. 2001. V. 86. P. 3512-3515.

108. Rubino C., de Vathaire F., Dottorini M.E. et al. Second primary malignancies in thyroid cancer patients // Brit. J. of Canc. 2003. P. 89. P. 1638-1644.

109. Genardiere E., Meimier F., Parmentier C. et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer // Brit. J. of Canc. 1997. V. 75. P. 734-739.

110. Ford D., Giridharan S., McConkey C. External beam radiotherapy in the management of differentiated thyroid cancer // Clin. Oncol. (Royal College of Radiology). 2003. V. 15. P. 337-341.

111. Mazzarotto R., Cesaro M.G., Lora 0. The role of external beam radiotherapy in the management of differentiated thyroid cancer // Biomed. and Pharmacoth. 2000. V. 54. P. 345-349.

112. Droz J.P., Schlumberger M., Rougier P. et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy // Tumori. 1990. V. 76. P. 480-483.

113. Pacini F., Vitti P., Martino E. Treatment of refractory thyroid cancer with adriamycin // Drugs Under Experim. and Clin. Res. 1984. V. 10. P. 911-916.

114. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease // Semin. in Surg. Oncol. 1999. V. 16. P. 34-41.

115. Santini F., Bottici V., Elisei R. et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer // J. of Clin. Endocr. and Met. 2002. V. 87. P. 4160-4165.

116. Braga-Brasaria M., Ringel M.D. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer // J. of Clin.Endocr. and Met. 2003. V. 88. P. 1947-1960.


Для цитирования:


- -. ЕВРОПЕЙСКИЙ КОНСЕНСУС ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ ИЗ ФОЛЛИКУЛЯРНОГО ЭПИТЕЛИЯ. Клиническая и экспериментальная тиреоидология. 2006;2(3):10-30. https://doi.org/10.14341/ket20062310-30

For citation:


. EVROPEYSKIY KONSENSUS PO DIAGNOSTIKE I LEChENIYu DIFFERENTsIROVANNOGO RAKA ShchITOVIDNOY ZhELEZY IZ FOLLIKULYaRNOGO EPITELIYa. Clinical and experimental thyroidology. 2006;2(3):10-30. (In Russ.) https://doi.org/10.14341/ket20062310-30

Просмотров: 62


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)